Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Endocrinology · Type A Insulin Resistance Syndrome

The Long View: Monitoring, Family, and Future Health

At a Glance

Type A insulin resistance syndrome is lifelong and can change unpredictably: some people maintain normal blood sugar, while others develop diabetes. Regular health checks, family testing, and specialist pregnancy care help detect changes and plan safely.

Living with Type A Insulin Resistance Syndrome (TAIRS) means managing a condition that can change and evolve over your lifetime. Because the mutation in your insulin receptor is permanent, your health journey is one of careful, long-term monitoring rather than a one-time treatment [1].

A Variable Long-Term Outlook

One of the most striking things about TAIRS is how much it varies from person to person—even among members of the same family who share the exact same genetic mutation [2].

Your “metabolic course” may not be a straight line. For some, the condition stays stable as high insulin without high blood sugar (euglycemia) for decades. Others may develop diabetes in their teens or 20s, while some might not see blood sugar rise until their 50s or 70s [3][2]. Because the clinical course can be so unpredictable, your medical team will likely perform regular screenings to catch changes early [4].

Monitoring for Complications

Monitoring frequency should be individualized. In addition to ongoing glucose assessment, blood pressure, renal function, lipids, liver health, and reproductive health checks, if you develop diabetes, you and your doctor should monitor for:

  • Retinopathy: Changes in the blood vessels of the eyes [5].
  • Nephropathy: Stress or damage to the kidneys, usually checked via a urine test for protein [5].
  • Neuropathy: Nerve damage, often felt as tingling or numbness in the hands and feet [5].
    (Do not assume that patients without diabetes automatically need the same complication schedule as people with established diabetes.)

Reproductive Health and Fertility

For females with TAIRS, the high insulin levels can have a significant impact on reproductive health. Up to 82% of postpubertal females with these mutations experience some form of hyperandrogenism or symptoms similar to PCOS, such as irregular periods and excess hair growth [3].

Fertility and Pregnancy

Pregnancy is possible with TAIRS, but it requires preconception genetic counseling and a specialized care team, including a maternal-fetal medicine (high-risk pregnancy) specialist [6].

  • Gestational Diabetes: Limited cohort estimates suggest high rates of gestational diabetes (between 20% and 53% in some series) for women with these mutations [3].
  • Insulin Requirements: Because pregnancy naturally increases insulin resistance, you may need very high doses of insulin (e.g., over 130 units per day has been reported in some series) to keep blood sugar stable [7].
  • Fetal Growth: Pregnancy outcomes depend on maternal glycemia, treatment, placental function, and whether the fetus inherited an INSR variant; strict monitoring is necessary as severe fetal insulin-signaling defects may contribute to growth restriction [3][8].

The Power of Family Testing (Cascade Screening)

Because TAIRS is a genetic condition, your diagnosis is a vital piece of information for your biological family. Cascade testing is the process of testing first-degree relatives (parents, siblings, and children) for a confirmed pathogenic or likely pathogenic variant, coordinated through genetic counseling [9].

Testing relatives with the variant is important because:

  1. Clinical Awareness: Relatives with the variant may experience symptoms like severe “crashes” in blood sugar after meals but have been misdiagnosed [1].
  2. Early Intervention: Finding the mutation early allows family members to start monitoring. Healthy lifestyle habits support general health, though they cannot correct an INSR receptor defect [9].
  3. Correcting Misdiagnosis: It may reveal that a relative’s “standard” Type 2 diabetes is actually TAIRS, which could completely change their treatment plan [10].

Survivorship and Support

While TAIRS is a lifelong condition, it is generally much milder than the more severe INSR disorders like Donohue syndrome [11]. Most people with TAIRS live full lives, though they must remain vigilant about their metabolic health. By staying connected with a specialist who understands rare insulin resistance, you can adapt your treatment as you age and enter different stages of life [12].

Common questions in this guide

Will everyone with Type A insulin resistance syndrome eventually develop diabetes?
No. The course varies widely: some people have very high insulin levels with normal blood sugar for decades, while others develop diabetes in adolescence, adulthood, or later life. Regular, individualized blood sugar checks help identify changes early.
What health checks are important for someone with TAIRS?
Monitoring may include blood sugar, blood pressure, kidney function, cholesterol and other blood fats, liver health, and reproductive health. If diabetes develops, clinicians may add eye, kidney-protein, and nerve checks, but people without diabetes may not need the same schedule. The frequency should be tailored to the individual.
Can someone with TAIRS have a safe pregnancy?
Pregnancy is possible, but it should be planned with preconception genetic counseling and a maternal-fetal medicine specialist. Pregnancy can increase insulin needs and the chance of gestational diabetes, so blood sugar, treatment, placental function, and fetal growth may need close monitoring.
Should my parents, siblings, or children be tested for TAIRS?
When a pathogenic or likely pathogenic INSR variant is confirmed, cascade testing can be discussed for biological first-degree relatives—parents, siblings, and children—with a genetic counselor. Finding the variant may lead to earlier monitoring and can clarify whether symptoms or a diabetes diagnosis are related to TAIRS.
What is the long-term outlook for people with Type A insulin resistance syndrome?
TAIRS is lifelong, but it is generally much milder than severe INSR disorders such as Donohue syndrome. Most people live full lives, although their blood sugar, reproductive health, and other metabolic measures need ongoing follow-up. The outlook can vary from person to person, even within the same family.
Can TAIRS cause low blood sugar after meals?
Some people with TAIRS may have marked blood sugar drops after eating, sometimes called late-phase hypoglycemia. A recurring pattern of symptoms or low readings should be discussed with the care team, which can decide whether a supervised evaluation is appropriate.

Get notified when new evidence is published on Insulin-resistance syndrome type A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Family with two novel in cis INSR gene variants: Phenotypic evolution with age.

    Sotiriou G, Mertzanian A, Raptopoulou ME, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2026; (35(4)):351-356 doi:10.1297/cpe.2026-0014.

    PMID: 42825299
  2. 2

    A family with type A insulin resistance syndrome caused by a novel insulin receptor mutation.

    Horikawa O, Ugi S, Takayoshi T, et al.

    Endocrinology, diabetes & metabolism case reports 2023; (2023(2)).

    PMID: 37042492
  3. 3

    Comprehensive assessment of the genotype-phenotype spectrum and treatment for monoallelic insulin receptoropathy in a cohort of 505 people.

    Brown R, Xu J, Luan J, et al.

    Research square 2026; doi:10.21203/rs.3.rs-10884175/v1.

    PMID: 42856426
  4. 4

    Diagnostic and management challenges from childhood, puberty through to transition in severe insulin resistance due to insulin receptor mutations.

    Wei C, Burren CP

    Pediatric diabetes 2017; (18(8)):835-838 doi:10.1111/pedi.12486.

    PMID: 28093873
  5. 5

    Type 2 diabetes mellitus.

    DeFronzo RA, Ferrannini E, Groop L, et al.

    Nature reviews. Disease primers 2015; (1()):15019 doi:10.1038/nrdp.2015.19.

    PMID: 27189025
  6. 6

    Management of pregnancy with metformin: Case reports for genetic insulin resistance syndrome and a literature review for gestational and type 2 diabetes.

    Yoshimura K, Hirota Y, Hamaguchi T, et al.

    Journal of diabetes investigation 2025; (16(9)):1663-1669 doi:10.1111/jdi.70105.

    PMID: 40587328
  7. 7

    Case report: Glycaemic management and pregnancy outcomes in a woman with an insulin receptor mutation, p.Met1180Lys.

    Crowley MT, Goulden E, Sanchez-Lechuga B, et al.

    Clinical diabetes and endocrinology 2024; (10(1)):5 doi:10.1186/s40842-024-00166-9.

    PMID: 38461278
  8. 8

    Pre-gestational diabetes in a young woman with a pathogenic INSR missense mutation, p.(Met1180Lys).

    Prehn EL, Crowley M, Fennell D, et al.

    Endocrinology, diabetes & metabolism case reports 2025; (2025(1)).

    PMID: 39922186
  9. 9

    Diazoxide-unresponsive Hyperinsulinemic Hypoglycaemia in a Preterm Infant with Heterozygous Insulin Receptor Gene Mutation

    Poon SWY, Chung BHY, Wong MSC, Tsang AMC

    Journal of clinical research in pediatric endocrinology 2025; (17(1)):115-119 doi:10.4274/jcrpe.galenos.2023.2022-12-10.

    PMID: 37074094
  10. 10

    Hyperinsulinemic hypoglycemia due to pathogenic INSR variants: metabolic signature, phenotypic overlap, and semidominant inheritance.

    Marcelino do Nascimento R, Dos Santos A, Guadagnini D, et al.

    Frontiers in endocrinology 2026; (17()):1716020 doi:10.3389/fendo.2026.1716020.

    PMID: 42181197
  11. 11

    A novel homozygous missense mutation in the insulin receptor gene results in an atypical presentation of Rabson-Mendenhall syndrome.

    Ben Abdelaziz R, Ben Chehida A, Azzouz H, et al.

    European journal of medical genetics 2016; (59(1)):16-9.

    PMID: 26691667
  12. 12

    Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.

    Martínez-Montoro JI, Pinzón-Martín JL, Damas-Fuentes M, et al.

    Frontiers in endocrinology 2022; (13()):838887 doi:10.3389/fendo.2022.838887.

    PMID: 35498407

This page is for informational purposes only and does not constitute medical advice. Discuss your mutation, monitoring schedule, and reproductive plans with your endocrinology, genetics, and pregnancy-care team.